Meta-analysis on Effectiveness and Safety of Moxifloxacin in Treatment of Mul…

Moxifloxacin, a fourth generation fluoroquinolone, which has good antibacterial activity against both Gram-positive cocci and Gram-negative bacteria. To date, there are no meta-analysis to evaluate the efficacy and safety of moxifloxacin for multidrug resistant tuberculosis (MDR-TB) treatment. This meta-analysis to explore the efficacy and safety of the moxifloxacin in treatment of MDR-TB in ad…

Common Eye Diseases and their Management

It is a pleasure to welcome two new authors who have contributed to the third edition of “Common Eye Diseases”: Peter Galloway and Andrew Browning. Six years have passed since the last edition but even in this relatively short time there have been significant advances in the diagnosis and management of eye disease and an update has become necessary. Each author has taken a block of chapter…

Effectiveness of Ciprofloxacin, Levofloxacin, or Moxifloxacin for Treatment o…

The purpose of this study was to quantitatively compare, in a rabbit keratitis model, the levels of effectiveness of moxifloxacin, levofloxacin, and ciprofloxacin for the treatment of Staphylococcus aureus isolates of diverse antibiotic susceptibilities. Rabbit eyes were intrastromally injected with approximately 100 CFU of methicillin sensitive or methicillin-resistant S. aureus (MSSA or MRSA,…

Penetration of 0.3% ciprofloxacin, 0.3% ofloxacin, and 0.5% moxifloxacin into…

We aimed to quantify the penetration of ciprofloxacin, ofloxacin, and moxifloxacin into the cornea and aqueous humor of cadaver eyes. A total of 60 enucleated eyes, not eligible for corneal transplantation, were divided into three groups and immersed in commercial solutions of 0.3% ciprofloxacin, 0.3% ofloxacin, or 0.5% moxifloxacin for 10 min. Whole corneas and samples of aqueous humor were th…

Moxifloxacin: a review of the microbiological, pharmacological, clinical and …

Edition

-

ISBN/ISSN

-

Collation

-

Series Title

-

Call Number

-

Moxifloxacin

Moxifloxacin (MOXI: 8-methoxy-quinolone), and quinolones in general, exert their effects by trapping a DNA drug enzyme complex and specifically inhibiting ATP-dependent enzymes topoisomerase II (DNA gyrase) and topoisomerase IV.

Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): Efficacy and S…

Intravenous/oral moxifloxacin therapy was efficacious and safe for hospitalized elderly patients with CAP, achieving 190% cure in all severity and age subgroups, and was associated with faster clinical recovery than intravenous/oral levofloxacin therapy, with a comparable safety profile.

Pharmacokinetics of Moxifloxacin and Levofloxacin in Intensive Care Unit Pati…

Extended daily dialysis (EDD) is increasingly popular in the treatment of acute renal failure (ARF). EDD could remove drugs to a much different degree compared with intermittent standard hemodialysis or continuous renal replacement therapies; however, there are only scarce data on how EDD influences the pharmacokinetics of frequently used drugs. The aim of this study was to determine the pha…

Moxifloxacin versus levofloxacin against acute exacerbations of chronic bronc…

We compared the efficacy and safety of moxifloxacin and levofloxacin for the treatment of patients with acute exacerbations of chronic bronchitis (AECB) using a prospective, randomized, double blind, parallel-group clinical trial design. A total of 563 patients with AECB were enrolled (437 efficacy-valid) at 34 centers in Mexico, Argentina, Brazil, Colombia, and Peru. Patients were randomized t…

Moxifloxacin Pharmacokinetics, Cardiac Safety, and Dosing for the Treatment o…

Moxifloxacin is a recommended drug for rifampin-resistant tuberculosis (RR-TB) treatment, but there is limited pediatric pharmacokinetic and safety data, especially in young children. We characterize moxifloxacin population pharmacokinetics and QT interval prolongation and evaluate optimal dosing in children with RR-TB